Physician profile
Christopher Rizzi
NPI 1427390160
$1,274.17
in general payments reported to CMS, 2019-2025
11 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Plastic Surgery Within The Head & Neck provider received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $134 · 2022: $263 · 2023: $232 · 2024: $191 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $363.22 | 2019-2025 | Xpress Loprofile, Scopis Ent |
| Smith+Nephew, INC. | $197.77 | 2023-2025 | Halo, Tula, Coblation |
| Aerin Medical INC. | $174.27 | 2023-2024 | |
| Glaxosmithkline, LLC. | $155.66 | 2021-2022 | |
| Intersect Ent, INC. | $128.70 | 2022 | |
| Acclarent, INC | $98.29 | 2022-2023 | Trudi Nav Cable |
| Regeneron Healthcare Solutions, INC. | $55.25 | 2022-2023 | Dupixent |
| Phathom Pharmaceuticals, INC. | $39.67 | 2024 | Voquezna |
| Amgen INC. | $30.62 | 2025 | Tezspire |
| Optinose US, INC. | $16.47 | 2021 | |
| Aroa Biosurgery Incorporated | $14.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rizzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.